Download MendeleyDesign of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.
Wittlinger, F., Heppner, D.E., To, C., Gunther, M., Shin, B.H., Rana, J.K., Schmoker, A.M., Beyett, T.S., Berger, L.M., Berger, B.T., Bauer, N., Vasta, J.D., Corona, C.R., Robers, M.B., Knapp, S., Janne, P.A., Eck, M.J., Laufer, S.A.(2022) J Med Chem 65: 1370-1383
- PubMed: 34668706
- DOI: https://doi.org/10.1021/acs.jmedchem.1c00848
- Primary Citation of Related Structures:
6WA2, 6WAK, 6WXN - PubMed Abstract:
Inhibitors targeting the epidermal growth factor receptor (EGFR) are an effective therapy for patients with non-small cell lung cancer harboring drug-sensitive activating mutations in the EGFR kinase domain. Drug resistance due to treatment-acquired mutations has motivated the development of successive generations of inhibitors that bind in the ATP site. The third-generation agent osimertinib is now a first-line treatment for this disease. Recently, allosteric inhibitors have been developed to overcome drug-resistant mutations that confer a resistance to osimertinib. Here, we present the structure-guided design and synthesis of a mutant-selective lead compound, which consists of a pyridinyl imidazole-fused benzylisoindolinedione scaffold that simultaneously occupies the orthosteric and allosteric sites. The compound potently inhibits enzymatic activity in L858R/T790M/C797S mutant EGFR (4.9 nM), with a significantly lower activity for wild-type EGFR (47 nM). Additionally, this compound achieves modest cetuximab-independent and mutant-selective cellular efficacies on the L858R (1.2 μM) and L858R/T790M (4.4 μM) variants.
Organizational Affiliation:
Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.
